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The p53 Heterozygous Knockout Mouse as a Model for Chemical
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Heterozygous p53 knockout mice were investigated as a potential model for vascular tumor car-
cinogenesis. Groups of20 male mice were exposed by gavage for 6 months to the vascular car-
cinogen urethane at 1, 10, or 100 mg/kg body weight/day. Wild-type and heterozygous p53
knockout control groups were exposed bygavage to the vehide alone. Another group of20 male
mice received etlimonene by gavage (dtlimonene is noncarcinogenic in mice). The high dose of
urethane caused early mortality in the majority ofmice associated with histopathologic evidence
oftoxicityandtumors, including ahigh incidence ofbenign and malignantvascular tumors, inall
animals. At the intermediate dose, toxicity was less marked and 3 of20 mice had tumors; mice
that receivedthe lowdose did nothave signs oftoxicityor neoplasia. The two control groups had
no tumors and the ilimonene group had one tumorofthe prostate, which was considered spon-
taneous. We conclude that the p53 knockout mouse is a useful tool for investigating vascular
tumorogenesis. Key words: carcinogenicity models, p53 knockout mouse, vascular tumors.
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The p53 knockout mouse is the subject of
great interest for its potential as a tool to
study chemical carcinogenesis. The heterozy-
gote could be used in carcinogenicity testing
strategies that would potentially reduce the
number of full-scale lifetime studies in con-
ventional mouse models (1,2). Because het-
erozygous p53 knockout mice should be
more sensitive to carcinogens than normal
mice, such rodent bioassays would use fewer
animals and take less time. Furthermore,
because heterozygous p53 knockout mice
have a low incidence of tumors until 9-12
months ofage, it should be easier to identify
the treatment-related effects of chemicals in
a mouse strain with a low background of
spontaneous cancers (3,4). After 12 months
ofage, the rate oftumor development accel-
erates and by 18 months ofage, 50% ofthe
heterozygous mice have succumbed to
tumors, mainly osteosarcomas, malignant
lymphomas, and hemangiosarcomas.
Therefore, 6 months is a suitable test dura-
tion; the expected yield of spontaneous
tumors should be low.
Mice, as with other experimental species,
have a strain-dependent profile of tumor
types. Hepatocellular tumors are common in
many strains of mice and are the subject of
much discussion with respect to their rele-
vance in carcinogen evaluation (5,6). Lung
tumors and lymphoreticular tumors are also
relatively common. Although vascular
tumors are also found, they usually occur at
a relatively low incidence (7,8). The most
commonly found tumors in p53 homozy-
gous and heterozygous knockout mice are
sarcomas, malignant lymphomas, and
hemangiosarcomas (4).
Vascular tumors are increased in the
mouse by relatively potent chemical car-
cinogens such as vinyl chloride (9). Because
of the nature of vascular tissue, which does
not lend itself easily to mechanistic studies,
little is known about the susceptibility of
this tissue.
To explore the potential of the p53
knockout mouse for studying vascular
tumors we selected the genotoxic compound
urethane, which produces these tumors in
lifetime studies in mice. Urethane, which is
genotoxic via the formation of a reactive
electrophilic metabolite, vinyl carbamate
epoxide (10), has well-documented carcino-
genic activity in rodent models; studies date
back more than 20 years (11). Urethane was
previously used as an anesthetic, but is also a
natural compound found in low concentra-
tions in many fermentation products (12).
One ofthe assumptions with the knock-
out model is that a mutation at the intact
p53 allele is necessary for development ofthe
carcinogenic process. In principle, nongeno-
toxic compounds that induce tumors by
other mechanisms should be negative in this
system. Therefore, d-limonene, which is nei-
ther genotoxic nor carcinogenic in mice but
is carcinogenic in the male rat by a nongeno-
toxic mechanism (13-15), was included as a
negative control substance.
The criteria established for assessing the
usefulness of this model were zero incidence
of vascular tumors in untreated p53 knock-
out mice, untreated wild-type mice, and in
d-limonene-treated p53 knockout mice (at 6
months); a high incidence ofvascular tumors
in p53 knockout mice that receive a toxic
dose ofurethane; and a dose-related decrease
in vascular tumors in p53 knockout mice
with lower doses ofurethane.
Materials and Methods
Heterozygous p53 knockout mice
(C57B1/6Tac-[KO] Trp53N5-T) and wild-
type (C57B1/6Tac-[KO] Trp53N5-W) mice
were purchased from Taconic (Germantown,
NY). These mice are derived from a chimera
based on two inbred strains (129/Sv x
C57Bl/6) (16). Four groups of 20 male het-
erozygous p53 knockout mice (p53+1-), 8
weeks of age at the start of treatment, were
dosed daily by gavage [5 mL/kg body weight
(bw)] with urethane at 1, 10, and 100
mg/kg/day, respectively, or with d-limonene
at 250 mg/kg/day for at least 180 days. These
dose levels were based on published mouse
bioassay data (17-19). Two control groups
of 20 mice each, one heterozygous p53
knockout mouse (p53Y-) and one wild type
(p53Y1'), received vehicle alone for the same
period of time. Urethane (batch 125H0318,
a white powder of 100% purity) and d-
limonene (batch 075H3530, a colorless liq-
uid of 99.4% purity) were suspended or
diluted in 0.5% methylcellulose and 0.2%
Tween 80 in sterile water. Urethane and d-
limonene were purchased from Sigma
Chemical Company (St. Louis, MO). The
methylcellulose and Tween 80 were pur-
chased from Fluka (Buchs, Switzerland).
The animals were checked daily for clini-
cal signs, moribundity, and mortality.
Detailed physical examinations were per-
formed weekly during the treatment period.
Body weight and food consumption were
measuredweeklyduring the first 14 weeks and
monthly thereafter. All animals were necrop-
sied; adrenal gland, brain, heart, kidney, liver,
spleen, testis, and thymus were weighed fresh
at final sacrifice only. The tissues (adrenal
glands, aorta, articular surface, bone, bone
marrow, brain, cecum, colon, duodenum, epi-
didymides, esophagus, eyes, gallbladder,
Harderian glands, heart, ileum, jejunum, kid-
neys, larynx, liver, lung, mammary gland,
mesenteric lymph nodes, ovaries, pancreas,
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Figure 1. Body weight curves: mean body weight
of the urethane-treated (1, 10, or 100 mg/kg
hw/day), d-limonene-treated (250 mg/kg bw/day)
or vehicle control-treated heterozygous p53
knockout mice as compared to vehicle control-
treated wild-type mice over the 6-month study
period.
parathyroid glands, pituitary gland, prostate,
rectum, sciatic nerve, seminal vesicles, skeletal
muscle, skin, spinal cord, spleen, stomach,
submaxillary glands, submaxillary lymph
nodes, testes, thymus, thyroid glands, tongue,
trachea, urinary bladder, uterus, vagina, and all
gross lesions detected at necropsy) were fixed
in 10% neutral buffered formalin with the
exception of the eyes, Harderian glands, testes,
and epididymides; these were fixed in
Davidson's fixative (20). All of the standard
protocol tissues (with the exception of the lar-
ynx) were embedded in paraffin wax, sec-
tioned at 5 pm, and stained with hematoxylin
and eosin for routine light microscopic
histopathologic examinations.
During the study, the care and use of
animals were in accordance with regulations
of the Guide for the Care and Use of
Laboratory Animals (21) and the directive
86/6O9ICEE (22).
Results
p53 Knockout Mice Versus
Wild-Type Mice
The body weight of the p53 knockout mice
was higher than the body weight of wild-
type animals from the end of the first week
of the study (Figure 1). This difference,
which ranged between 3 and 8%, was statis-
tically significant during most of the study
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and was related, in part, to di
food consumption between the I
p53 knockout versus wild-type n
In this study, there were no
organ weight or gross findings
between the untreated p53 knm
and their wild-type counterparts.
examinations revealed midzona
fatty change characterized by th
tion ofintracellular large vacuol
thep53 knockouts as compared
wild type. In the kidney, 200/c
knockout mice showed minor
changes (cortical basophilic
inflammatory changes (peripelh
clear cell infiltrates) as compare
5%, respectively, in the wild
Focal epithelial hyperplasia of
was noted in 20% ofthe p53 kn
as compared to none in the
Mononuclear cell infiltrate of
was noted in 25% of the p53 kr
as compared to 5% in the wild t
plastic changes were noted in t:
p53knockouts or in the wild-typ
Urethane Treatment: p53 B
Mice
Clinicalobservations, mortality,
The highest dose of urethane
mg/kg bw/day) was toxic fron
month in the study, and it ha
effects on body weight (Figure
mg/kg bw/day, the mean body
5.5% lower than the vehicle cot
from day 85 of the study; thi
reached up to 15% at the end
By the end ofthe 6-month exp
17 of the 20 mice at this dose
Table 2. Incidence summary tabli
observed lesions.
Vascular tissue
Endothelial proliferation, liver
Angiectasis, liver
B: hemangioma, liver/heart
M: hemangiosarcoma, liver,
spleen/abdominal cavity
Benign and/or malignant tumors
M: lymphomas, lymphoreticular
tissue
B: adenoma, lung
M: sarcoma, subcutis
Focus of cellularalteration,
eosinophilic, liver
Focus of cellular alteration,
clear cell, liver
M: hepatocellular carcinoma, liver
Oval cell proliferation, liver
Retinal atrophy, bilateral, eyes
B: adenoma, prostate
Tumor-bearing animalsg
Wil
vet
Twenty animals per group were availabli
and malignant tumors bythe letter M.
aDose level 0 mg/kg/day. bDose level 1 n
m),/kg/day. fOnly 13 animals were availat
ifferences in had been sacrificed moribund (Table 1). The perirenal fat of one high-dose urethane
heterozygous probable cause of death in the highest dose mouse. Proliferative vascular changes con-
nice. group was internal hemorrhage related to sisting of hemangiomatous-like endothelial
differences in and most likely secondary to vascular tumors hyperplasia were present in the liver of 2 of
at necropsy (Table 1). Although a few sporadic deaths 20 mice and in the heart of a single mouse
ockout mice were noted in other groups, these were con- from the 100 mg/kg/day urethane group.
Microscopic sidered unrelated to treatment and did not Neoplasms of the vasculature, benign
J hepatocyte exceed 2 of20 in any group. At necropsy, all hemangioma (Figure 2), and/or malignant
ie accumula- of the high-dose urethane p53 knockout hemangiosarcoma (Figure 3) were noted in
es in 25% of mice presented with masses or red colored the liver ofa total of 18 (90%) mice treated
to 0% in the spots on the liver. Dark fluid, presumably at 100 mg/kg/day urethane (Table 2). Of
) of the p53 blood, was often present in the abdominal the mice from the 100 mg/kg/day urethane
degenerative and/or thoracic cavities in animals that died. group, we found hemangiomas in 70%,
tubules) or Ten of 20 mice had enlarged spleens. Other hemangiosarcomas in 40%, and both
tic mononu- changes noted at necropsy in the high-dose hemangioma and hemangiosarcoma in 20%.
d to 10 and urethane p53 knockout mice included red These vascular tumors were generally multi-
[-type mice. spots on the stomach mucosa and/or ple, affecting a large surface area ofthe liver
the prostate markedly large thymus in a small proportion section. Large thrombi were generally associ-
ockout mice of mice. Mice treated with urethane at 1 or ated with the presence of vascular neo-
wild type. 10 mg/kg bw/day showed no obvious differ- plasms. At this dose level, single occurrences
the pancreas ences from control during the live phase of of hemangiosarcoma were noted in the
iockout mice the study. At necropsy of the 10 mg/kg spleen and in the abdominal cavity and a
ype. No neo- bw/day group, 8 of20 mice ofhad red spots hemangioma was present in the heart of a
'he untreated on the liver, dark fluid was noted in the tho- single mouse. In the 10 mg/kg/day group,
te mice. racic cavity of two mice, and an enlarged multiple hemangiomas were noted in the
spleen in two mice. No significant organ liver ofa single treatedp53knockout mouse.
iLnockout weight changes were noted at this dose level. These changes were generally correlated with
At 1 mg/kg/day only one mouse had a red the gross observations made at necropsy. At
andnecropsy. spot on the liver. 1 mg/kg/day, no vascular changes of any
tested (100 Histopathology (Table 2). Vascular sys- type were detected at microscopic examina-
n the fourth tem. We noted nonproliferative vascular tion ofany ofthe organs examined.
,d significant changes in a high proportion ofmice treated Liver. At 100 mg/kg/day urethane, we
c 1). At 100 with the two higher dose levels of urethane. noted large areas ofhepatocyte zonal necro-
y weight was Angiectasis, consisting of dilated vascular sis affecting essentially the centrilobular or
ntrol animals spaces lined by endothelial cells and filled midzonal areas (functional zones 1 and 2) of
is difference with erythrocytes, was present in the liver of the hepatic lobules in 70% of the heterozy-
of the study. 8 of 20 and 9 of 20 p53 knockout mice at gous p53 knockout treated mice. These
osure period, 10 and 100 mg/kg/day, respectively. Asingle degenerative changes, which were located in
had died or focus of angiectasis was also noted in the the liver parenchyma not affected by the
presence oftumors, were sometimes associat-
e for the number of animals affected by selected microscopically ed with signs of regeneration ofhepatocytes
such as marked cytomegaly or increased
Id-type p5J+1-) p5J+1-b p53+1-) p53+1-l p53+1-) number of mitotic figures. Foci of cellular
hiclea vehiclea urethaneb urethanec urethaned d-limonenee alteration, eosinophilic type, were noted in
0 0 0 0 2 0 10% ofthe treated mice. Oval cell hyperpla-
0 0 0 8 9 0 sia was also noted in 10% ofthe mice at this
0 0 0 1 14 0 dose level. Hepatocellular carcinomas, which
O 0 0 0 8 0 are closely associated with hemangioma or
0 0 0 1 18 0 hemangiosarcoma, were diagnosed in 20%
0 0 0 1 3 0 of the mice treated at 100 mg/kg/day. Foci
of cellular alteration, clear cell type, were
0 0 0 0 5 0 noted in 30%, midzonal hepatocyte fatty
0 0 0 1 1 0 change in 35%, and hepatocyte hypertrophy
O 0 0 0 2 0 in 20% of the 10 mg/kg/day treated mice.
0 0 0 6 0 0 No significant liver changes were noted in
the 1 mg/kg/day group.
0 0 0 0 4 0 Thymus. We found malignant lym-
0 0 0 0 2 0 phomas (Figure 4) in 1 of20 (5%) and 3 of
0 0 0 0 l21 0 20 (15%) of the mice treated at 10 and 100
0 0 0 3 20 1 mg/kg/day, respectively. These neoplasms, originating in the thymus, were spreading to
le for microscopic examinations. Benign tumors are distinguished by the letter B other tissues (liver, kidney, lung, spleen, heart,
ng/kg/day. cDose level 10 mg/kg/day. dDose level 100 mg/kg/day. 0ose level 250 adrenal gland, sternum, subcutis, aorta, and
bleforthe eye in the 100 mg/kg/day group. 9Alltypes oftumors. spinal cord). Six (30%) ofthe 100 mg/kg/day
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mice had generalized atrophy/involution
of the thymus as did one mouse at 10
mg/kg/day. Cortical lymphocytolysis/apopto-
sis was noted in 5 (25%) of the mice that
received 100 mg/kg/day. No changes were
noted at 1 mg/kg/day.
Lung. We found bronchioloalveolar ade-
nomas (Figure 5) in 5 mice (25%) treated at
100 mglkg/day. Interstitial mononuclear cell
infiltrate of the pulmonary parenchyma was
noted in 15 of20 (75%) ofthe mice at the
same dose level. No significant changes were
found at 10 and 1 mg/kg/day.
Subcutis. A large subcutaneous sarcoma
was present in a single p53 knockout mouse
treated at 10 mg/kg/day and in one treated
at 100 mg/kg/day.
Testis. Twenty-five percent of the mice
from the 10 and 100 mg/kg/day group had
diffuse atrophy ofthe seminiferous tubules.
Eye. Twelve of 13 (92%) of the mice
treated with urethane at 100 mg/kg/day had
bilateral retinal atrophy consisting of the
complete loss of the bacillary, outer nuclear,
and outer plexiform layers ofthe eye.
d-Limonene Treatment: p53
Knockout Mice
Clinicalobservations, mortality, andnecropsy.
No significant changes were found in the d-
limonene-treated p53 knockout mice as
compared to the untreated control group.
Histopathology. We observed hyperplasia
ofthe nonglandular stomach in 85% ofthe
d-limonene-treated p53 knockout mice.
With the exception of a single adenoma of
the prostate, no neoplasms were observed in
this dose group.
Discussion
The p53 knockout mouse model is used in
fundamental studies of the mechanisms of
carcinogenesis (3,23-26). To better under-
stand the role ofthep53gene in this process,
the model is also under validation for its use-
fulness as a more sensitive rodent model for
identifying potential carcinogens (1,3).
Our purpose was to test whether het-
erozygous p53-deficient mice are a good
model to detect vascular tumors caused by
genotoxic carcinogens using urethane as a
positive control. Urethane is a well-known
carcinogen that forms a reactive electrophilic
metabolite (10). Mirvish et al. (11) showed
that urethane induced malignant lymphoma,
hepatoma (depending on the strain), mam-
mary carcinoma, hemangioma, and lung
adenoma in mice. In a later study, Schmihl
et al. (2X) reported lung adenoma, mamma-
ry tumors, and hemangioendothelioma after
2 years of treatment. Although these are old
studies, the findings are consistent from one
study to another. In the present study, our
findings are similar to those ofMirvish et al.
(11) and Schmihl et al. (27): lung adenoma,
hemangioma and/or hemangiosarcoma,
hepatocellular tumors and malignant lym-
phoma were observed in urethane-treated
mice. We did not observe mammary tumors
because only male animals were used. The
incidence ofvascular tumors inp53-deficient
mice administered with 100 mg/kg/day ure-
thane was high (90%). The other tumor
types (malignant lymphoma and sarcoma),
which are usually detected in aging p53
Figure 2. Benign hemangioma in the liver of a heterozygous p53 knockout
mouse treated with urethane at 100 mg/kg for 180 days. The lesion is character-
ized by dilated, blood-filled spaces lined by a single layer of prominent uniform
endothelial cells without atypia. They are differentiated from angiectasis, which
consists of cystic dilated normal blood vessels with no evidence of endothelial
proliferation. Bar= 100 pm.
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Figure 4. Malignant lymphoma in the thymus of a heterozygous p53 knockout
mouse treated with urethane at 100 mg/kg for 180 days. The tumor is invading
the surrounding fattytissue. Bar = 100 pm.
Figure 3. Malignant hemangiosarcoma in the liver of a heterozygous p53
knockout mouse treated with urethane at 100 mg/kg for 180 days. The lesion is
characterized by solid growth of pleiomorphic endothelial cells presenting a
fibrosarcomatous pattern. Bar = 100 pm.
Figure 5. A small benign bronchioloalveolar adenoma in the lung of a mouse
treated with urethane at 100 mg/kg for 180 days. Bar = 100 pm.
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knockout mice, were also present in the 100
mg/kg/day urethane group. We also
obtained a dose-related effect with urethane
treatment; no tumor was detected at 1
mg/kg/day and there was only a low inci-
dence oftumors at 10 mglkg/day.
Inai et al. (19) used a range of urethane
doses that can be compared to ours for the
purposes of making conclusions about the
sensitivity ofthe model. In their study, dose
levels equivalent to 1, 10, and 100 mg/kg
bw/day were administered in drinking water
to B6C3F1 mice for 70 weeks. Their study
also found early death in the highest dose
(600 ppm; approximately 100 mg/kg/day).
In addition, the authors considered the early
mortality to be attributable to the rupture of
the vascular tumors, which occurred in
approximately 80% of the high dose mice.
Inai et al. (19) showed a fewvascular tumors
at 10 mg/kg/day; at lower doses the inci-
dence was comparable to background. Their
study showed a lower threshold for detecting
lung tumors (significant increases were seen
at 10 mg/kg/day), whereas we had none at
this dose. However, Inai et al. (19) had an
18.4% incidence of this tumor in controls.
Considering the differences in experimental
design, the coherence ofthe results between
these two studies appears remarkably good.
No tumors were seen in untreated het-
erozygous p53 knockout mice or in the
wild-type mice. d-Limonene, which is not
genotoxic or carcinogenic in mice, did not
induce any treatment-related tumors in het-
erozygous p53 knockout mice. The single
adenoma ofthe prostate was considered inci-
dental. d-Limonene caused signs of chronic
irritation of the nonglandular stomach that
were associated with hyperplasia but not
neoplasia. Field and Roe (28) reported simi-
lar lesions, associated with the irritant effect
ofthe compound.
Thus, thep53model proved efficient for
the induction of vascular tumors. It was
possible to induce a high incidence of
hemangioma and/or hemangiosarcoma in
the heterozygousp53 knockout mice treated
with urethane in a short period of time as
compared to a classical 2-year bioassay for
carcinogenicity studies. The appearance of
the tumors was dose related with neither
neoplastic nor nonneoplastic proliferative
findings at the low dose. There were no vas-
cular tumors in the untreated animals or in
animals treated with d-limonene. Therefore,
we consider that our three criteria for the
usefulness of the model were met, namely:
zero incidence ofvascular tumors in untreat-
ed p53 knockout mice, untreated wild-type
mice, and in d-limonene-treated p53 knock-
out mice (at 6 months); a high incidence of
vascular tumors in p53 knockout mice
receiving toxic doses ofurethane; and a dose-
related decrease in vascular tumors in p53
knockout mice with lower doses ofurethane.
In conclusion, the heterozygous p53
knockout mouse seems to be a good model
for identifying vascular tumors. The essen-
tially nonexistent level ofvascular tumors in
control p53 knockout mice might make this
system particularly suitable for studying low
potency compounds suspected of being vas-
cular carcinogens.
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